Table 1 |
|||
| A summary of characteristics of included studies | |||
| Author | Method | Participants and settings | Interventions/control |
| Kreiss 1992 [15] | Unblinded RCT | 138 female sex workers Nairobi, Kenya | 1000 mg N-9 sponge/placebo |
| Richardson 2001 [19] | Double blind RCT | 278 female sex workers, Mombasa, Kenya | 52.5 mg N-9 gel/placebo |
| Roddy 1998 [17] | Double blind RCT | 1292 female sex workers, Cameroon | 70 mg N-9 film/placebo |
| Roddy 2002 [16] | Unblinded RCT | 1251 women (non sex workers) from clinics or pharmacy, Cameroon | 100 mg N-9 gel/No intervention |
| Van Damme 2002 [18] | Triple blind RCT | 892 women sex workers from Benin, Cote d’Ivoire, South Africa, Thailand | 52.5 mg N-9/placebo |
| Halpern 2008 [21] | Double blind RCT | 1644 women from bars, market, other common gathering areas, Lagos and Port Harcourt, Nigeria | 6% CS gel/placebo |
| Van Damme 2008 [24] | Double blind RCT | 1428 women, South Africa, Uganda, Benin and India (Chennai, Bangalore) | 6% CS gel/placebo |
| Felblum 2008 [20] | Double blind RCT | 2153 women from local market areas, bars hostels, military barracks and colleges, Lagos and Ibadan, Nigeria | 1.0% C31G (SAVVY) gel/placebo |
| Peterson 2007 [23] | Double blind RCT | 2142 women from high HIV transmission areas including markets, bars, hotels, Accra and Kumasi, Ghana | 1% C31G (SAVVY) gel/placebo |
| Skoler-Karpoff 2008 [27] | Double blind RCT | 6,202 women from local health clinics, malls, churches, taxi ranks, other community venues, University of Cape Town, University of Limpopo-Medunsa campus Ga-Rankuwa and Medical Research Council, Durban, South Africa | Carraguard gel/placebo |
| Abdul Karim 2011 [26] | RCT Double blind | 3101 women in Malawi, South Africa, Zambia , Zimbawe, USA | BufferGel/ 0.5% PRO2000/placebo |
| McCormack 2010 [22] | RCT Double blind | 6,651 women, three sites in South Africa; Mwanza, Tanzania; Entebbe, Uganda; Mazambuka, Zambia | 0.5% PRO2000 gel/placebo |
| Abdul Karim 2010 [25] | RCT Double blind | 1085 at urban and rural clinic, Kwa-Zulu Natal, South Africa | 1% tenofovir gel/placebo |
CS, cellulose sulphate; N-9, nonoxynol-9; RCT, randomised controlled trials; USA, United States of America.
Obiero et al. BMC Infectious Diseases 2012 12:289 doi:10.1186/1471-2334-12-289
